We have previously observed that while several cytokines were able to modulate histocompatibility antigens, that not all cytokines were similar in the pattern of augmenting histocompatibility antigen expression. Whereas IL-4, GM-CSF and IFN-gamma all enhanced the expression of HLA-DR and HLA-DP antigens on monocytes, only IFN-gamma augmented the expression of HLA-DQ. While IFN-gamma and IFN-alpha augmented class I (HLA-A,B,C antigens) on monocytes, IL-4 and GM-CSF did not. These studies were extended to look at other cell lines. THP-1 is a human monocyte-like cell line. Although this cell has receptors for IL-4, like monocytes, it did not respond to IL-4 or GM-CSF in the augmentation of HLA-DR antigen expression. The THP-1 cell line responds dramatically to IFN-gamma. Differentiating agents, such as DMSO, PMA, retinoic acid, did not alter the response of THP-1 cells to IL-4 or GM-CSF. Two other non- myeloid cell lines were also examined. Normal human endothelial cells, and a human adenocarcinoma cell line, had increased expression of HLA-DR antigens after treatment with IFN-gamma, but not after treatment with either IL-4 or GM-CSF. These studies will help us understand not only histocompatibility antigen expression, but cytokine function as well.

Agency
National Institute of Health (NIH)
Institute
Food and Drug Administration (FDA)
Type
Intramural Research (Z01)
Project #
1Z01BD003010-03
Application #
3804740
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1991
Total Cost
Indirect Cost